Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1629-1635

  MacCallum, J ^a,b   Cummings, J ^a   Dixon, J M ^a   Miller, W R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

Author keywords

4 Hydroxytamoxifen; Desmethyltamoxifen; Response; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN;

BODY WEIGHT; BREAST CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANCE; DRUG TISSUE LEVEL; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SHORT SURVEY; SOLID PHASE EXTRACTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BODY WEIGHT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN;

EID: 0034012358     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (35)

1. Campbell DA, Ritchie AA, Langdon S, Anderson TJ and Miller WR (1997) Tamoxifen induced apoptosis in R-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat 45: 99-107
2. Daniel CP, Gaskell SJ, Bishop H and Nicholson RI (1979) Determination of tamoxifen and an unhydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography mass spectometry. J Endocrinol 83: 401-408
3. Daniel P, Gaskell SJ, Bishop H, Campbell C and Robertson RI (1981) Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 17: 1183-1189
4. Forouhi P, Walsh JS, Anderson TJ and Chetty U (1994) Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic therapy. Br J Surg 81: 223-225
5. Foster BD, Cavener DR and Parl FF (1991) Binding analysis of the oestrogen receptor to its specific DNA target site in human breast cancer tissue. Cancer Res 51: 3405-3410
6. Gottardis MM and Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumours in athymic mice after long-term antioestrogen administration. Cancer Res 48: 5183-5187
7. Gottardis MM, Jiang SY, Jeng MH and Jordan VC (1989) Inhibition of tamoxifen stimulated growth of an MCF-7 variant in athymic mice by novel steroidal antioestrogens. Cancer Res 49: 4090-4093
8. Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM and Wei LL (1990) T47DCo cell, genetically unstable and containing oestrogen receptor mutations, are a model for the progression of breast cancer to hormone resistance. Cancer Res 50: 6208-6217
9. Horwitz KB (1993) Can hormone 'resistant' breast cancer cells be inappropriately stimulated by tamoxifen? Ann NY Acad Sci 684: 63-74
10. Johnstone SRD, Haynes BP, Smith IE, Jarman M, Sacks NPM, Ebbs SR and Dowsett M (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342: 1521-1522
11. Katzenellenbogen BS, Miller MA, Mullick A and Sheen YT (1985) Antioestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with oestrogen receptors and additional antioestrogen binding sites. Breast Cancer Res Treat 5: 231-243
12. Koga M and Sutherland RL (1987) Epidermal growth factor partially reverses the inhibition effects of antioestrogens on T47D human breast cancer cell growth. Biochem Biophys Res Commun 146: 739-745
13. Langan-Fahey SM, Tormey DC and Jordan VC (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26 (8): 883-888
14. Lerner LJ and Jordan VC (1990) Development of antioestrogens and their use in breast cancer. Cancer Res 50: 4177-4189
15. Lien EA, Solheim E and Ueland PM (1991a) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51: 4837-4844
16. Lien EA, Webster K, Lonning PE, Solheim E and Ueland PM (1991b) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641-645
17. Lim CK, Chow LCL, Yuan Z-X and Smith LL (1993) High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. Biomed Chromatogr 7: 311-314
18. Love CDB, Muir BB, MacCallum J, Miller WR, Scrimgeour JB, Leonard RCS and Dixon JM (1997) Relation between tamoxifen duration and endometrial thickness. Breast Cancer Res Treat 46 (Suppl): 26
19. MacCallum J, Cummings J, Dixon JM and Miller WR (1996) Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J Chromatogr B 678: 317-323
20. MacCallum J, Cummings J, Dixon JM and Miller WR (1997) Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues. J Chromatogr B 698: 269-275
21. Miller MA and Katzenellenbogen BS (1983) Characterization and quantitation of antioestrogen binding sites in oestrogen receptor-positive and negative human breast cancer cell lines. Cancer Res 43: 3094-3100
22. Miller MA, Lippman ME and Katzenellenbogen BS (1984) Antioestrogen binding in antioestrogen growth resistant oestrogen-responsive clonal variants of MCF-7 human breast cancer cells. Cancer Res 44: 5038-5045
23. Murphy LC and Dozlaw H (1989) Variant oestrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3: 687-693
24. Murphy LC and Sutherland RL (1981) A high affinity binding site for the antioestrogens, tamoxifen and Cl 628 in immature rat uterine cytosol which is distinct from oestrogen receptors. J Endocrinol 91: 155-161
25. Osborne CK (1995) Tamoxifen metabolism as a mechanism for resistance. Endocrine-related Cancer 2: 53-58
26. Osborne CK, Coronado EB and Robinson JP (1987) Human breast cancer in the athymic nude mouse: cytostatic effect of long-term antioestrogen therapy. Eur J Cancer Clin Oncol 23: 1189-1196
27. Osborne CK, Coronado E, Allred DC, Wiebe VY and Degregorio M (1991) Acquired tamoxifen resistance: correlation with reduced breast tumour levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482
28. Osborne CK, Wiebe VY, McGuire WL, Ciocca DR and Degregorio MW (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumours from breast cancer patients. J Clin Oncol 10: 304-310
29. Raam S, Robert N, Pappas CA and Tamura H (1988) Defective oestrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst 80: 756-761
30. Robinson SP and Jordan VC (1988) Metabolism of steroid modifying anticancer agents. Pharmacol Ther 36: 41-103
31. Robinson SP and Jordan VC (1994) Metabolism of antihormonal anticancer agents. In: Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, Powlis C (ed). pp. 279-289 (section 5.2). Pergamon Press: Oxford
32. Robinson SP, Langan-Fahey and Jordan VC (1989) Tamoxifen metabolism in the athymic mouse: implications for the study of antitumour effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 25: 1769-1776
33. Scott GK, Kushner P, Vigne P and Benz CC (1991) Truncated forms of DNA-hinding oestrogen receptor. J Clin Invest 88: 700-706
34. Tormey DC, Simon R. Lippman ME, Bull JM and Myers CE (1976) Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep 60: 1451-1459
35. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R and Jordan VC (1993) Investigation of the mechanism of tamoxifen-stimulated breast tumour growth with non-isomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806-812